FDA Did Not Change Position on Ivermectin Use, Contrary to Online Claims
SciCheck Digest
In response to a civil suit, lawyers for the Food and Drug Administration described the agency’s warnings about the unapproved use of ivermectin to treat COVID-19 as “recommendations.” Although that description doesn’t reveal new information, some conservative outlets have falsely claimed it’s an “outrageous” revelation and a change in the FDA’s position.
There are no cures for COVID-19, but an increasing number of evidence-based treatments have been identified. Most of these have emergency use authorization, rather than full approval, from the Food and Drug Administration.
At the end of December 2021, the FDA authorized for emergency use the first oral antivirals for COVID-19, Pfizer’s Paxlovid and Merck’s molnupiravir. Both drugs are authorized for patients with mild-to-moderate COVID-19 who are at high risk of severe disease. The pills should be given as early as possible and no later than five days after symptoms begin.
Paxlovid consists of nirmatrelvir, a protease inhibitor that prevents replication of the coronavirus, or SARS-CoV-2; and ritonavir, a drug that
You’re reading a preview, subscribe to read more.
Start your free 30 days